Figures & data
Table 1 Clinical Characteristics of Patients Receiving Lenvatinib Treatment for Advanced-Stage Hepatocellular Carcinoma
Table 2 Univariate and Multivariate Analyses of Prognostic Factor Affecting Progression-Free Survival of Patients with Hepatocellular Carcinoma Under Lenvatinib Treatment
Table 3 Univariate and Multivariate Analyses of Prognostic Factor Affecting Overall Survival of Patients with Hepatocellular Carcinoma Under Lenvatinib Treatment
Figure 1 Kaplan–Meier survival curves in patients with advanced hepatocellular carcinoma following lenvatinib treatment. (A) Progression-free survival curve, and the median time was 7.1 months. (B) Overall survival curve, and the median time was 17.7 months.
![Figure 1 Kaplan–Meier survival curves in patients with advanced hepatocellular carcinoma following lenvatinib treatment. (A) Progression-free survival curve, and the median time was 7.1 months. (B) Overall survival curve, and the median time was 17.7 months.](/cms/asset/b53cfa2a-4a77-4a25-9754-beb36fe0ae21/djhc_a_12155584_f0001_c.jpg)
Figure 2 Comparison of cumulative survival curves according to AFP >10% reduction within the first 4 weeks of treatment for patients with baseline serum AFP ≥10 ng/mL (n = 97). (A) Progression-free survival curve. (B) Overall survival curve.
![Figure 2 Comparison of cumulative survival curves according to AFP >10% reduction within the first 4 weeks of treatment for patients with baseline serum AFP ≥10 ng/mL (n = 97). (A) Progression-free survival curve. (B) Overall survival curve.](/cms/asset/b4ec6d47-65e1-4612-91fe-792208d5dee0/djhc_a_12155584_f0002_c.jpg)
Figure 3 Comparison of cumulative survival curves according to AFP >10% reduction within the first 4 weeks of treatment for patients with baseline serum AFP >400 ng/mL (n = 46). (A) Progression-free survival curve. (B) Overall survival curve.
![Figure 3 Comparison of cumulative survival curves according to AFP >10% reduction within the first 4 weeks of treatment for patients with baseline serum AFP >400 ng/mL (n = 46). (A) Progression-free survival curve. (B) Overall survival curve.](/cms/asset/aced1512-b73f-4ddc-8419-755608cd4330/djhc_a_12155584_f0003_c.jpg)
Figure 4 Comparison of cumulative survival curves according to neutrophil-lymphocyte ratio (NLR). Patients with pre-treatment NLR > 4.07 (n = 55) showed a significant worse outcome than those patients with NLR ≤ 4.07 (n = 88). (A) Progression-free survival curve. (p = 0.014) (B) Overall survival curve. (p = 0.010).
![Figure 4 Comparison of cumulative survival curves according to neutrophil-lymphocyte ratio (NLR). Patients with pre-treatment NLR > 4.07 (n = 55) showed a significant worse outcome than those patients with NLR ≤ 4.07 (n = 88). (A) Progression-free survival curve. (p = 0.014) (B) Overall survival curve. (p = 0.010).](/cms/asset/05c1b2f2-f1a3-45ef-a4e2-9ad2eaf0f8f2/djhc_a_12155584_f0004_c.jpg)